DocMorris AG/€DOCM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About DocMorris AG
DocMorris AG operates in the healthcare industry, focusing on providing pharmaceutical services as a leading online pharmacy in Europe. The company offers a wide range of prescription and over-the-counter medications, healthcare products, and services through its e-commerce platform. Founded in 2000, DocMorris is headquartered in Heerlen, the Netherlands. It holds a unique strategic position by leveraging digital technology to enhance customer convenience and streamline the medication procurement process. The company’s core strength lies in its extensive network and efficient delivery system, catering to a broad customer base across multiple European countries.
- Ticker
- €DOCM
- Sector
- Consumer Essentials
- Primary listing
- XGAT
- Employees
- 1,337
- Headquarters
- Frauenfeld, Switzerland
- Website
- corporate.docmorris.com/en
DocMorris AG Metrics
BasicAdvanced
€1B
-
-€2.83
1.86
-
Price and volume
Market cap
€1B
Beta
1.86
52-week high
€20.72
52-week low
€4.32
Average daily volume
447K
Financial strength
Current ratio
1.875
Quick ratio
1.529
Long term debt to equity
0.73
Total debt to equity
0.742
Interest coverage (TTM)
-4.92%
Profitability
EBITDA (TTM)
-81.933
Gross margin (TTM)
22.10%
Net profit margin (TTM)
-10.65%
Operating margin (TTM)
-7.25%
Effective tax rate (TTM)
-11.93%
Revenue per employee (TTM)
€953,530
Management effectiveness
Return on assets (TTM)
-6.37%
Return on equity (TTM)
-30.05%
Valuation
Price to revenue (TTM)
0.761
Price to book
2.53
Price to tangible book (TTM)
-7.87
Price to free cash flow (TTM)
-11.113
Free cash flow yield (TTM)
-9.00%
Free cash flow per share (TTM)
-1.817
Growth
Revenue change (TTM)
11.29%
Earnings per share change (TTM)
-55.78%
3-year revenue growth (CAGR)
9.55%
10-year revenue growth (CAGR)
3.22%
3-year earnings per share growth (CAGR)
-19.24%
10-year earnings per share growth (CAGR)
5.97%
Bulls say / Bears say
German prescription revenue rose 78.3% year on year in Q3, helping lift external revenue by 21.5%; the active customer base also grew by 1.5 million to 13.1 million. This points to strong demand for DocMorris’s digital prescription service. (Deutsche Börse)
Digital Services revenue grew 46.1% in Q3 and 62% in the first nine months, giving DocMorris a fast-growing business beyond medicine sales. The company said the segment’s earnings contribution also increased. (Deutsche Börse)
DocMorris reached CHF0.6 million of adjusted EBITDA in Q3, a quarter ahead of its target, and raised its 2026 revenue and earnings guidance. This is evidence that stronger sales and tighter cost control are starting to improve operating performance. (Deutsche Börse)
Cash and current financial assets fell to CHF99.2 million at June-end from CHF159.5 million at year-end, while the first-half net loss was CHF53.1 million. Management still targets free-cash-flow breakeven only during 2027, leaving funding and execution risk. (DocMorris)
The improvement in profitability is not yet broad-based: Q3 adjusted EBITDA was only CHF0.6 million, and the company still expects a full-year adjusted EBITDA loss. Investors need to see the improvement persist and translate into unadjusted profits. (Deutsche Börse, DocMorris)
DocMorris remains heavily reliant on Germany: the country generated CHF326.3 million of Q3 external revenue out of CHF342.7 million, while Europe contributed only CHF16.4 million. That concentration leaves results particularly exposed to changes in the German market. (Deutsche Börse)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.